Medical World News® Deep Dive: Making Cell and Gene Therapy Practical

Video

Josh Ludwig detailed to CancerNetwork® how ScaleReady can help make cell and gene therapy widely practical and viable for patients with cancer.

In a recent episode of Deep Dive from the Medical World News® broadcast, CancerNetwork® spoke with Josh Ludwig, the global director of commercial operations at ScaleReady, about how a joint venture launched in January 2021 between Bio-Techne, Fresenius Kabi, and Wilson Wolf is uniquely positioned to make cell and gene therapy practical and viable for patients with cancer.

Ludwig discussed how ScaleReady can support the entire industry, now and into the future, with a manufacturing platform that delivers a high throughput and efficient use of space. He also detailed G-Rex closed-system bioreactors, important processes for successful commercialization of cell and gene therapy, and future efforts utilizing ScaleReady.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences™ channels.

Recent Videos
Optimal cancer survivorship care may entail collaboration between a treating oncologist and a cancer survivorship expert.
Survivors of cancer may experience an increased risk of having organ, cardiac, or lung disease following prior anti-cancer therapy.
Performing ablation and injecting tumor sites with immunotherapy may be “synergistic”, according to Jason R. Williams, MD, DABR.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
The Together for Supportive Cancer Care coalition may advance the national conversation in ensuring comprehensive care for all patients with cancer.
Health care organizations have come together to form the Together for Supportive Cancer Care coalition to address gaps in supportive cancer care services.
Further optimizing a PROTAC that targets MDM2 may lead to human clinical trials among patients with cancer harboring p53 mutations.
Related Content
A panel of cancer survivorship experts outline major areas of focus and care models for improving outcomes among pediatric and adult survivors of cancer.

Individually Optimizing Cancer Outcomes Through a Mission of Survivorship Care

Russ Conroy
December 10th 2024
Article

A panel of cancer survivorship experts outline major areas of focus and care models for improving outcomes among pediatric and adult survivors of cancer.

Jessica Cheng, MD, highlights how physical medicine and rehabilitation may help optimize function and performance status in patients with cancer.

Improving Quality of Life in Cancer With Physical Medicine & Rehabilitation

Jessica Cheng, MD
September 9th 2024
Podcast

Jessica Cheng, MD, highlights how physical medicine and rehabilitation may help optimize function and performance status in patients with cancer.

Assessing 2024 Oncology Advances and Looking Ahead

Assessing 2024 Oncology Advances and Looking Ahead

Neil M. Iyengar, MD
December 4th 2024
Article

Neil M. Iyengar, MD, highlights the biggest advances in oncology, and where he expects the field to move next.

Cancer vaccines may pair well with other forms of immunotherapy in the treatment of patients with cancer, according to Catherine J. Wu, MD.

Taking a “Cross-Cutting Approach” With Cancer Vaccinations

Catherine J. Wu, MD
August 12th 2024
Podcast

Cancer vaccines may pair well with other forms of immunotherapy in the treatment of patients with cancer, according to Catherine J. Wu, MD.

ASTRO Guideline Recommends EBRT for Symptomatic Bone Metastases

ASTRO Guideline Recommends EBRT for Symptomatic Bone Metastases

Tim Cortese
November 28th 2024
Article

ASTRO assembled a task force to create a guideline for the administration of palliative external beam radiation therapy for patients with symptomatic bone metastases.

T-DXd Sequencing and Treatment Options in the Tumor-Agnostic Setting

T-DXd Sequencing and Treatment Options in the Tumor-Agnostic Setting

ONCOLOGY Staff
November 15th 2024
Article

HER-directed treatment approaches in the tumor-agnostic field were the highlight of the discussion for a panel of experts who convened at WCLC 2024.